Abstract of the oral presentation at 13th EUCHIS 31st May-3rd June 2017.

More than 2000 publications and 20 published clinical trials within the last 12 month show that chitosan and chitosan derivatives are still attractive for the medical industry. As producer of well defined and pure chitosans and chitosan derivatives for pharmaceutical applications, with more than one hundred different specification for chitosans on the market and around 300 production batches per year HMC is always on the pulse of the market and in contact with regulatories and pharmaceutical companies worldwide.

Media attention for the HMC⁺ - Research. The highly pure Chitosan-products by HMC⁺ are in demand around the world. In addition to our production of highly pure chitosans and chitosan derivatives, we work together with our partners on new applications and other high-tech products.